The global
infectious disease diagnostics market is set to witness a
CAGR of ~7% in the next 5 years. Increasing prevalence of
infectious diseases, growing threat of emerging infectious diseases, rise in
demand for point-of-care testing, technological advancements, rising awareness
and initiatives to control infectious diseases spread, and increasing concerns
about antimicrobial resistance, are some of the key factors driving the
infectious disease diagnostics market.
Infectious-disease diagnostics refers to the procedure of
detecting, identifying and characterizing the causative agent of an infectious
disease. The diagnosis is based on clinical presentation or more rigorous
diagnostic tests, such as culturing of the infectious agent, microscopy,
biochemical screens and molecular methods among others. The diagnosis involves
methods and equipment used to detect infectious agents like bacteria, viruses,
fungi, and parasites in human samples. The diagnosis methods can include
traditional techniques like culture and microscopy to advanced molecular
methods like polymerase chain reaction (PCR), next-generation sequencing (NGS),
and rapid point-of-care (POC) tests. Timely diagnostics helps is preventing
disease outbreaks, and track the disease course and response to treatment.
Download a free sample report for in-depth market insights
https://meditechinsights.com/infectious-disease-diagnostics-market/request-sample/
Growing threat of emerging infectious diseases to drive
market growth
Emerging infectious diseases are either recently appearing
or rapidly spreading infections, that can be caused by previously undetected,
unknown, newly recognized, or re-emerging infectious agents. WHO has cautioned
that the infectious diseases are emerging at a rapid rate, and since past few
decades various new infectious diseases have been discovered, like SARS, MERS,
Ebola, chikungunya, avian flu, swine flu, Zika and most recently COVID-19.
Outbreaks of such infectious diseases can spread rapidly, causing significant
losses to health and livelihood. An effective strategy is to prevent or control
their spread at an early stage is early detection and identification of disease
or disease-causing agents. Rapid and accurate identification of these agents is
essential to prevent outbreaks with the correct control measure. The threat of
emerging infectious diseases has highlighted the importance of early detection
thus fueling the demand for conventional and advanced diagnostics.
Increasing concerns about antimicrobial resistance to
boost market growth
Antimicrobial Resistance (AMR) is a phenomenon that occurs
when the infectious agents stop responding to antimicrobial medicines.
According to WHO, AMR is one of the top global public health and development
threats, and the estimated number of deaths attributed to bacterial AMR were
1.27 million in 2019 globally. Over the years microbes have increasingly
developed, acquired antimicrobial resistance to many drugs owing to high
selection pressure from increasing use and misuse of antibiotics. Widespread overuse
and misuse of antibiotics greatly contributes to antibiotic resistance.
Diagnostic tests play an important role here as they help determine when and
not antibiotics are an appropriate treatment, thus ensuring right treatment is
provided at the right time. This is driving the demand for advanced diagnostics
that support better antimicrobial stewardship.
Competitive Landscape Analysis
The global infectious disease diagnostics market is marked
by the presence of established and emerging market players such as F.
Hoffmann-La Roche Ltd; Abbott; Biomérieux; Thermo Fisher Scientific Inc.;
Siemens Healthineers AG; DH Life Sciences, LLC; BD (Becton, Dickinson and
Company); Hologic, Inc.; Qiagen; and Revvity; among
others. Some of the key strategies adopted by market players include new
product development, strategic partnerships and collaborations, and geographic
expansion.
Unlock key
data with a sample report for competitive analysis:
https://meditechinsights.com/infectious-disease-diagnostics-market/request-sample/
Global Infectious Disease Diagnostics Market Segmentation
This report by Medi-Tech Insights provides the size of
the global infectious disease diagnostics market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on product and service, testing type, sample type, technology, disease type,
and end user.
Market Size & Forecast (2023-2030), By Product and
Service, USD Million
- Instruments
- Reagents,
Kits and Consumables
- Software
and Services
Market Size & Forecast (2023-2030), By Testing Type,
USD Million
- Laboratory
Testing
- POC
Testing
Market Size & Forecast (2023-2030), By Sample Type,
USD Million
- Blood,
Serum, and Plasma
- Urine
- Others
Market Size & Forecast (2023-2030), By Technology,
USD Million
- Immunodiagnostics
- Molecular
Diagnostics
- Microbiology
- Others
Market Size & Forecast (2023-2030), By Disease Type,
USD Million
- Hepatitis
- Tuberculosis
(TB)
- Sexually
Transmitted Infections
- Hospital-Acquired
Infections (HAIs)
- Influenza
- Others
Market Size & Forecast (2023-2030), By End User, USD
Million
- Hospitals
& Clinics
- Diagnostic
Laboratories
- Academic
& Research Institutes
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech
Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment